 Recombinant human erythropoietin vascular accesses incidence vascular access clotting years first months control period second period months recombinant human erythropoietin epoetin average duration months range months patients overall incidence vascular access monthly rate events patient-month year period Distribution number events patient periods patients episode Patients recurrent events episodes second period differences incidence vascular access epoetin treated patients untreated patients events patient-year events patient-year period events patient-year epoetin vascular access clotting